- Home
- CATO vs ICCM Comparison
CATO vs ICCM Comparison
Compare CATO & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CATO | ICCM |
|---|---|---|
| Founded | 1946 | 2006 |
| Country | United States | Israel |
| Employees | 7000 | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.5M | 45.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CATO | ICCM |
|---|---|---|
| Price | $3.39 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 55.7K | ★ 403.0K |
| Earning Date | 11-20-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $660,062,000.00 | $2,975,000.00 |
| Revenue This Year | N/A | $13.67 |
| Revenue Next Year | N/A | $38.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.19 | $0.59 |
| 52 Week High | $4.92 | $1.66 |
Technical Indicators
Market Signals| Indicator | CATO | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 41.99 |
| Support Level | $3.28 | $0.67 |
| Resistance Level | $3.60 | $0.72 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 77.19 | 62.50 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.